Using Yttrium-90 to improve liver surgery outcomes for cancer patients
Yittrium-90 radiation lobectomy: Dose optimization and prediction of FLR hypertrophy to enable resection of HCC
This study is looking at a new way to help people with liver cancer who can’t have surgery by using a special type of radiation treatment that aims to help the liver heal while keeping it safe, and it will involve some advanced imaging to see how well the treatment is working.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10675427 on NIH RePORTER |
What this research studies
This research focuses on enhancing treatment options for patients with unresectable hepatocellular carcinoma (HCC) by using a technique called Yttrium-90 radiation lobectomy. The study aims to optimize the radiation dose to promote liver regeneration while minimizing risks of liver failure. Patients will undergo advanced imaging techniques to monitor liver changes and assess the effectiveness of the treatment. By understanding how the liver responds to this therapy, the research seeks to improve surgical outcomes for patients who may not otherwise be candidates for surgery.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with unresectable hepatocellular carcinoma who have insufficient future liver remnant due to underlying liver disease.
Not a fit: Patients with resectable HCC or those who do not have liver disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enable more patients with liver cancer to undergo potentially curative surgeries by improving liver function and safety.
How similar studies have performed: Preliminary data suggests that similar approaches using Yttrium-90 have shown promise, but this specific method is still being explored for its optimal application.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Lewandowski, Robert J — Northwestern University at Chicago
- Study coordinator: Lewandowski, Robert J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.